Dergiler / Türk Dermatoloji Dergisi / 2019 / Cilt: 13 - Sayı: 1

The Importance of Baseline Screening Investigations and Modified Severity Weighted Assessment Tool in Patients with Early Stage Mycosis Fungoides: A Four-year Retrospective Study

Sayfa
1–7
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

High mSWAT scores, elevated beta-2 microglobulin and LDH levels, and plaque-type lesions were more frequent in non-responder patients.Conclusion: Our study demonstrates that extensive screening tests may not be very meaningful in patients with early-stage MF. mSWAT scores, beta-2 microglobulin, and LDH tests should be evaluated as useful measurements in prediction the response to treatment.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The present study aims to evaluate the prognosis and response to treatment relationship of baseline clinical and hematological parameters including eosinophil counts, neutrophil/lymphocyte ratio, levels of lactate dehydrogenase (LDH) and beta-2 microglobulin, flow cytometry and initial modified Severity Weighted Assessment Tool (mSWAT) scores in patients with mycosis fungoides (MF).
📊
Temel Bulgular & Veri:Methods: Medical records of 112 patients with the diagnosis of early-stage MF were examined retrospectively.
💡
Sonuç & Katkı:High mSWAT scores, elevated beta-2 microglobulin and LDH levels, and plaque-type lesions were more frequent in non-responder patients.Conclusion: Our study demonstrates that extensive screening tests may not be very meaningful in patients with early-stage MF. mSWAT scores, beta-2 microglobulin, and LDH tests should be evaluated as useful measurements in prediction the response to treatment.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The present study aims to evaluate the prognosis and response to treatment relationship of baseline clinical and hematological parameters including eosinophil counts, neutrophil/lymphocyte ratio, levels of lactate dehydrogenase (LDH) and beta-2 microglobulin, flow cytometry and initial modified Severity Weighted Assessment Tool (mSWAT) scores in patients with mycosis fungoides (MF). Methods: Medical records of 112 patients with the diagnosis of early-stage MF were examined retrospectively. Data of the patient and disease characteristics, and baseline laboratory tests were reviewed and evaluated in terms of stage and treatment response. Results: In this study, patients were classified into two groups: responders and non-responders. Complete and partial responses were observed in 79 (70%) patients. Eight patients (7%) developed relapse in the follow-up period. In the staging groups (IA, IB, IIA), the frequency of elevated beta-2 microglobulin was different among all parameters. When the results were compared based on clinical responsiveness, until the time to diagnosis was significantly longer in non-responder patients than responders. High mSWAT scores, elevated beta-2 microglobulin and LDH levels, and plaque-type lesions were more frequent in non-responder patients.Conclusion: Our study demonstrates that extensive screening tests may not be very meaningful in patients with early-stage MF. mSWAT scores, beta-2 microglobulin, and LDH tests should be evaluated as useful measurements in prediction the response to treatment.

🔖

Bu Makaleye Atıf Yap

FALAY, M., ÖZET, G., YALÇIN, B., ŞAHİN, B., UYSAL, P. İ., AKDOĞAN, N. (2022). The Importance of Baseline Screening Investigations and Modified Severity Weighted Assessment Tool in Patients with Early Stage Mycosis Fungoides: A Four-year Retrospective Study. Türk Dermatoloji Dergisi, Cilt: 13 - Sayı: 1, 1–7. https://ajindex.com/articles/621540

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85. 2. van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504-10
  2. Hughes CF, Newland K, McCormack C, et al. Mycosis fungoides and Sezary syndrome: Current challenges in assessment, management and prognostic markers. Australas J Dermatol 2016;57:182-91
  3. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22
  4. Scarisbrick JJ, Kim YH, Whittaker SJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now? Br J Dermatol 2014;170:1226-36
  5. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011;29:2598-607
  6. Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 2015;33:3766-73
  7. Wernham AG, Shah F, Amel-Kashipaz R, et al. Stage I mycosis fungoides: frequent association with a favourable prognosis but disease progression and disease-specific mortality may occur. Br J Dermatol 2015;173:1295-7
  8. Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer 2013;49:2859-68
  9. Sanz-Bueno J, Lora D, Monsalvez V, et al. The new Cutaneous Lymphoma International Prognostic index (CLIPi) for early mycosis fungoides failed to identify prognostic groups in a cohort of Spanish patients. Br J Dermatol 2016;175:794-6
  10. Scarisbrick JJ. Prognostic factors in mycosis fungoides: international advances in the validation of prognostic indices. Br J Dermatol 2017;176:1129-30
  11. Schmid MH, Bird P, Dummer R